Astrazeneca plc is beefing up its cell therapy capabilities in immuno-oncology by acquiring Neogene Therapeutics BV for an initial outlay of $200 million. There’s up to $120 million more on the table for undisclosed milestones and what the companies called a “non-contingent consideration.” Even without the additional earnouts, the deal represents a profitable return for Neogene’s shareholders. The Amsterdam-based firm had raised $110 million in a series A round in 2020, which represented the largest A round in Europe that year. Since then, it has started to move its first program, an autologous engineered T-cell receptor (TCR) T-cell therapy directed against up to five neoantigens, toward a phase I trial in patients with solid tumors.